The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug Administration, which could begin this month and last three to 10 months. To alleviate the shortage, CDC recommends substituting the other skin test, Tubersol, for Aplisol and prioritizing high-risk groups for testing, among other actions. Monitor the status of the supply interruption here.

Related News Articles

Headline
The Food and Drug Administration approved the second generic naloxone nasal spray, an emergency treatment for known or suspected opioid overdose. The…
Headline
The House yesterday voted 392-28 to pass legislation (H.R. 7667) that would reauthorize Food and Drug Administration user fee programs, which provide funding…
Headline
The Department of Health and Human Services has launched a webpage to help health care providers and families locate infant formula during the current national…
Headline
President Biden yesterday invoked the Defense Production Act to ensure manufacturers have the necessary ingredients to make infant formula in the United States…
Headline
The House Energy and Commerce Health Subcommittee today passed, as amended, the Restoring Hope for Mental Health and Well-being Act (H.R. 7666),…
Headline
In a letter today, AHA asked GE Healthcare to provide additional information to help member hospitals manage the current shortage of GE intraveneous…